The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Chemotherapy in elderly patients with NSCLC
Rajwanth Veluswamy, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses chemotherapy in elderly patients with non-small cell cancer (NSCLC). The median age of lung cancer diagnosis is 70 in theUSA, however, elderly patients are frequently excluded from clinical trials, resulting in a lack of data to predict treatment outcomes in this patient population. Interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
